Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis

References

• Pisoni RL, Wikström B, Elder SJ, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006;21(12):3495–3505. DOI:10.1093/ndt/gfl461
   PubMed Web of Science ®Google Scholar
• Shirazian S, Aina O, Park Y, et al. Chronic kidney disease-associated pruritus: impact on quality of life and current management challenges. Int J Nephrol Renovasc Dis. 2017;10:11–26.
   PubMed Web of Science ®Google Scholar
• Sukul N, Karaboyas A, Csomor PA, et al. Self-reported pruritus and clinical, dialysis-related, and patient-reported outcomes in hemodialysis patients. Kidney Med. 2021;3(1):42–53.e41. DOI:10.1016/j.xkme.2020.08.011
   PubMedGoogle Scholar
• Rayner HC, Larkina M, Wang M, et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol. 2017;12(12):2000–2007. DOI:10.2215/CJN.03280317.
   PubMed Web of Science ®Google Scholar
• Weisbord SD, Fried LF, Mor MK, et al. Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol. 2007;2(5):960–967. DOI:10.2215/CJN.00990207
   PubMed Web of Science ®Google Scholar
• Aresi G, Rayner HC, Hassan L, et al. Reasons for underreporting of uremic pruritus in people with chronic kidney disease: a qualitative study. J Pain Symptom Manage. 2019;58(4):578–586.e572. DOI:10.1016/j.jpainsymman.2019.06.010
   PubMed Web of Science ®Google Scholar
• Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev. 2020;12(12):Cd011393.
   PubMedGoogle Scholar
• Simonsen E, Komenda P, Lerner B, et al. Treatment of uremic pruritus: a systematic review. Am J Kidney Dis. 2017;70(5):638–655. DOI:10.1053/j.ajkd.2017.05.018
   PubMed Web of Science ®Google Scholar
• Verduzco HA, Shirazian S. CKD-Associated pruritus: new insights into diagnosis, pathogenesis, and management. Kidney Int Rep. 2020;5(9):1387–1402.
   PubMed Web of Science ®Google Scholar
• Weiss M, Mettang T, Tschulena U, et al. Health-related quality of life in haemodialysis patients suffering from chronic itch: results from GEHIS (German Epidemiology Haemodialysis Itch Study). Qual Life Res. 2016;25(12):3097–3106.
   PubMed Web of Science ®Google Scholar
• Plewig N, Ofenloch R, Mettang T, et al. The course of chronic itch in hemodialysis patients: results of a 4-year follow-up study of GEHIS (German Epidemiological Hemodialysis Itch Study). J Eur Acad Dermatol Venereol. 2019;33(7):1429–1435.
   PubMed Web of Science ®Google Scholar
• Mettang T, Kremer AE. Uremic pruritus. Kidney Int. 2015;87(4):685–691.
   PubMed Web of Science ®Google Scholar
• Wang E, Sasaki J, Nakamura M, et al. Cutaneous carcinogenic risk of phototherapy: an updated comprehensive review. J Psoriasis Psoriatic Arthritis. 2015;1(1):44–51.
   Google Scholar
• Kuypers DR. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol. 2009;5(3):157–170.
   PubMedGoogle Scholar
• Patel TS, Freedman BI, Yosipovitch G. An update on pruritus associated with CKD. Am J Kidney Dis. 2007;50(1):11–20.
   PubMed Web of Science ®Google Scholar
• Zakrzewska-Pniewska B, Jedras M. Is pruritus in chronic uremic patients related to peripheral somatic and autonomic neuropathy? Study by R-R interval variation test (RRIV) and by sympathetic skin response (SSR). Neurophysiol Clin. 2001;31(3):181–193.
   PubMed Web of Science ®Google Scholar
• Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502–507. DOI:10.2340/00015555-1246
   PubMed Web of Science ®Google Scholar
• Kimmel M, Alscher DM, Dunst R, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant. 2006;21(3):749–755. DOI:10.1093/ndt/gfi204
   PubMed Web of Science ®Google Scholar
• Reddy VB, Iuga AO, Shimada SG, et al. Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease-activated receptors. J Neurosci. 2008;28(17):4331–4335.
   PubMed Web of Science ®Google Scholar
• Lanot A, Kottler D, Béchade C. Pruritus associated chronic kidney disease. Nephrol Ther. 2021;17(7):488–495.
   PubMed Web of Science ®Google Scholar
• Namer B, Carr R, Johanek LM, et al. Separate peripheral pathways for pruritus in man. J Neurophysiol. 2008;100(4):2062–2069.
   PubMed Web of Science ®Google Scholar
• Mathur VS, Lindberg J, Germain M, et al. A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5(8):1410–1419. DOI:10.2215/CJN.00100110
   PubMed Web of Science ®Google Scholar
• Shirazian S, Kline M, Sakhiya V, et al. Longitudinal predictors of uremic pruritus. J Ren Nutr. 2013;23(6):428–431. DOI:10.1053/j.jrn.2013.08.002
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Weiss M, Passlick-Deetjen J, et al. Laboratory and dialysis characteristics in hemodialysis patients suffering from chronic itch–results from a representative cross-sectional study. BMC Nephrol. 2015;16(1):184.
   PubMedGoogle Scholar
• Shirazian S, Spencer RH, Kilfeather SA, et al. 137 reduction of pruritus by difelikefalin correlates with reductions in markers for pruritus and inflammation in subjects undergoing hemodialysis. Am J Kidney Diseases. 2022;79(4):S42.
   Web of Science ®Google Scholar
• Rayner H, Baharani J, Smith S, et al. Uraemic pruritus: relief of itching by gabapentin and pregabalin. Nephron Clin Pract. 2012;122(3–4):75–79.
   PubMedGoogle Scholar
• Electronic Medicines Compendium. Kapruvia summary of product characteristics. 2022. [cited 2021 Apr]. Available from: https://www.medicines.org.uk/emc/product/13735/smpc/print
   Google Scholar
• Gardell LR, Spencer RH, Chalmers DT, et al. Preclinical profile of CR845: a novel, long-acting peripheral kappa opioid receptor agonist. Poster Presentation at the International Association for the Study of Pain, Glasgow, UK. https://ir.caratherapeutics.com/static-files/396df363-8031-47f6-b903-eca1df1df26f, (2008).
   Google Scholar
• Menzaghi F, Spencer R, Abrouk N, et al. (422) CR845, a peripheral kappa opioid, provides better pain relief with less nausea and vomiting than placebo in patients after bunionectomy. J Pain. 2015;16(4):S81.
   Web of Science ®Google Scholar
• Fishbane S, Jamal A, Munera C, et al. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med. 2020;382(3):222–232. . DOI:10.1056/NEJMoa1912770
   PubMed Web of Science ®Google Scholar
• Topf J, Wooldridge T, McCafferty K, et al. Efficacy of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis of KALM-1 and KALM-2 Phase 3 Studies. Kidney Medicine. 2022;4(8):100512. DOI:10.1016/j.xkme.2022.100512.
   PubMedGoogle Scholar
• Fishbane S, Wen W, Munera C, et al. Safety and tolerability of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis from the phase 3 clinical trial program. Kidney Medicine. 2022;4(8):100513. DOI:10.1016/j.xkme.2022.100513.
   PubMedGoogle Scholar
• Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142(5):1375–1390.
   PubMed Web of Science ®Google Scholar
• Manenti L, Tansinda P, Vaglio A. Uraemic pruritus: clinical characteristics, pathophysiology and treatment. Drugs. 2009;69(3):251–263.
   PubMed Web of Science ®Google Scholar
• Blachley JD, Blankenship DM, Menter A, et al. Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. Am J Kidney Dis. 1985;5(5):237–241.
   PubMed Web of Science ®Google Scholar
• Chou FF, Ho JC, Huang SC, et al. A study on pruritus after parathyroidectomy for secondary hyperparathyroidism. J Am Coll Surg. 2000;190(1):65–70.
   PubMed Web of Science ®Google Scholar
• Narita I, Alchi B, Omori K, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int. 2006;69(9):1626–1632. DOI:10.1038/sj.ki.5000251
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Yosipovitch G. Itching as a systemic disease. J Allergy Clin Immunol. 2019;144(2):375–380.
   PubMed Web of Science ®Google Scholar
• Elman S, Hynan LS, Gabriel V, et al. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587–593.
   PubMed Web of Science ®Google Scholar
• Lipman ZM, Paramasivam V, Yosipovitch G, et al. Clinical management of chronic kidney disease-associated pruritus: current treatment options and future approaches. Clin Kidney J. 2021;14(Supplement_3):i16–22.
   PubMedGoogle Scholar
• Kardon AP, Polgár E, Hachisuka J, et al. Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord. Neuron. 2014;82(3):573–586. DOI:10.1016/j.neuron.2014.02.046
   PubMed Web of Science ®Google Scholar
• Cowan A, Kehner GB, Inan S. Targeting Itch with Ligands Selective for κ Opioid Receptors. Handb Exp Pharmacol. 2015;226:291–314.
   PubMedGoogle Scholar
• Fishbane S, Wen W, Munera C, et al. Long-term safety and efficacy of difelikefalin in patients with chronic kidney disease-associated pruritus: analysis from KALM-1 and KALM-2. Am J Kidney Diseases. 2021;77(4):593–594.
   Web of Science ®Google Scholar
• US Food and Drug Administration. Korsuva Prescribing Information. 2021. [cited 2021 Apr]. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214916s000lbl.pdf
   Google Scholar
• Lipman ZM, Yosipovitch G. An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease. Expert Opin Pharmacother. 2021;22(5):549–555.
   PubMed Web of Science ®Google Scholar
• Kozono H, Yoshitani H, Nakano R. Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch(®) capsules 2.5 μg) in 3,762 hemodialysis patients with intractable pruritus. Int J Nephrol Renovasc Dis. 2018;11:9–24.
   PubMed Web of Science ®Google Scholar
• Mathur VS, Kumar J, Crawford PW, et al. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine er tablets for uremic pruritus. Am J Nephrol. 2017;46(6):450–458.
   PubMed Web of Science ®Google Scholar
• Duque MI, Yosipovitch G, Fleischer AB Jr., et al. Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol. 2005;52(3 Pt 1):519–521.
   PubMed Web of Science ®Google Scholar
• Pour-Reza-Gholi F, Nasrollahi A, Firouzan A, et al. Low-dose doxepin for treatment of pruritus in patients on hemodialysis. Iran J Kidney Dis. 2007;1(1):34–37.
   PubMedGoogle Scholar
• Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother. 1997;31(5):633–635.
   PubMed Web of Science ®Google Scholar
• Metze D, Reimann S, Beissert S, et al. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol. 1999;41(4):533–539.
   PubMed Web of Science ®Google Scholar
• Bigliardi PL, Stammer H, Jost G, et al. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol. 2007;56(6):979–988.
   PubMed Web of Science ®Google Scholar
• Phan NQ, Bernhard JD, Luger TA, et al. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63(4):680–688.
   PubMed Web of Science ®Google Scholar
• Szepietowski JC, Morita A, Tsuji T. Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus. Med Hypotheses. 2002;58(2):167–170.
   PubMed Web of Science ®Google Scholar
• Sherjeena PB, Binitha MP, Rajan U, et al. A controlled trial of narrowband ultraviolet B phototherapy for the treatment of uremic pruritus. Indian J Dermatol Venereol Leprol. 2017;83(2):247–249. DOI:10.4103/0378-6323.198464
   PubMed Web of Science ®Google Scholar
• Ada S, Seçkin D, Budakoğlu I, et al. Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study. J Am Acad Dermatol. 2005;53(1):149–151.
   PubMed Web of Science ®Google Scholar
• Sharma D, Kwatra SG. Thalidomide for the treatment of chronic refractory pruritus. J Am Acad Dermatol. 2016;74(2):363–369.
   PubMed Web of Science ®Google Scholar
• Silva S, Viana P, Lugon N, et al. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron. 1994;67(3):270–273.
   PubMed Web of Science ®Google Scholar
• Taylor CP. Mechanisms of action of gabapentin. Rev Neurol (Paris). 1997;153 Suppl 1:S39–45.
   PubMed Web of Science ®Google Scholar
• Eusebio-Alpapara KMV, Castillo RL, Dofitas BL. Gabapentin for uremic pruritus: a systematic review of randomized controlled trials. Int J Dermatol. 2020;59(4):412–422.
   PubMed Web of Science ®Google Scholar
• Ishida JH, McCulloch CE, Steinman MA, et al. Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. J Am Soc Nephrol. 2018;29(7):1970–1978.
   PubMed Web of Science ®Google Scholar
• Riccardi VM. A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching. Arch Dermatol. 1993;129(5):577–581.
   PubMedGoogle Scholar
• Amirkhanlou S, Rashedi A, Taherian J, et al. Comparison of gabapentin and ketotifen in treatment of uremic pruritus in hemodialysis patients. Pak J Med Sci. 2016;32(1):22–26.
   PubMed Web of Science ®Google Scholar
• Tarng DC, Cho YL, Liu HN, et al. Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron. 1996;72(4):617–622.
   PubMed Web of Science ®Google Scholar
• Breneman DL, Cardone JS, Blumsack RF, et al. Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol. 1992;26(1):91–94.
   PubMed Web of Science ®Google Scholar
• Young TA, Patel TS, Camacho F, et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatol Treat. 2009;20(2):76–81. DOI:10.1080/09546630802441218
   PubMed Web of Science ®Google Scholar
• Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat. 2005;13(2):97–103.
   PubMedGoogle Scholar
• Pakfetrat M, Malekmakan L, Hashemi N, et al. Sertraline can reduce uremic pruritus in hemodialysis patient: a double blind randomized clinical trial from Southern Iran. Hemodial Int. 2018;22(1):103–109.
   PubMed Web of Science ®Google Scholar
• Chan KY, Li CW, Wong H, et al. Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients. J Palliat Med. 2013;16(8):966–970. DOI:10.1089/jpm.2012.0504
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium. Serotonin prescribing information. 2020. [cited 2023 Apr]. Available from: https://www.medicines.org.uk/emc/product/7162/smpc
   Google Scholar
• Min S, Kim KW, Jung WM, et al. Acupuncture for histamine-induced itch: association with increased parasympathetic tone and connectivity of putamen-midcingulate cortex. Front Neurosci. 2019;13:215.
   PubMed Web of Science ®Google Scholar
• Panahi Y, Dashti-Khavidaki S, Farnood F, et al. Therapeutic effects of omega-3 fatty acids on chronic kidney disease-associated pruritus: a literature review. Adv Pharm Bull. 2016;6(4):509–514.
   PubMedGoogle Scholar
• Ghanei E, Zeinali J, Borghei M, et al. Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial. Iran Red Crescent Med J. 2012;14(9):515–522.
   PubMed Web of Science ®Google Scholar
• Morton CA, Lafferty M, Hau C, et al. Pruritus and skin hydration during dialysis. Nephrol Dial Transplant. 1996;11(10):2031–2036.
   PubMed Web of Science ®Google Scholar
• Hiroshige K, Kabashima N, Takasugi M, et al. Optimal dialysis improves uremic pruritus. Am J Kidney Dis. 1995;25(3):413–419.
   PubMed Web of Science ®Google Scholar
• Liakopoulos V, Krishnan M, Stefanidis I, et al. Improvement in uremic symptoms after increasing daily dialysate volume in patients on chronic peritoneal dialysis with declining renal function. Int Urol Nephrol. 2004;36(3):437–443. DOI:10.1007/s11255-004-8788-9
   PubMedGoogle Scholar
• Ko MJ, Wu HY, Chen HY, et al. Uremic pruritus, dialysis adequacy, and metabolic profiles in hemodialysis patients: a prospective 5-year cohort study. PLoS ONE. 2013;8(8):e71404. DOI:10.1371/journal.pone.0071404
   PubMed Web of Science ®Google Scholar
• Uchiumi N, Sakuma K, Sato S, et al. The clinical evaluation of novel polymethyl methacrylate membrane with a modified membrane surface: a multicenter pilot study. Renal Replacement Ther. 2018;4(1):32. DOI:10.1186/s41100-018-0170-y
   Google Scholar
• Lin HH, Liu YL, Liu JH, et al. Uremic pruritus, cytokines, and polymethylmethacrylate artificial kidney. Artif Organs. 2008;32(6):468–472. DOI:10.1111/j.1525-1594.2008.00568.x
   PubMed Web of Science ®Google Scholar
• Agarwal R, Burton J, Gallieni M, et al. Clin Kidney J, Sfac. 2022;16(1):30–40. DOI:10.1093/ckj/sfac187.
   PubMed Web of Science ®Google Scholar
• Raouf M, Atkinson TJ, Crumb MW, et al. Rational dosing of gabapentin and pregabalin in chronic kidney disease. J Pain Res. 2017;10:275–278.
   PubMed Web of Science ®Google Scholar
• Zand L, McKian KP, Qian Q. Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. Am j med. 2010;123(4):367–373.
   PubMed Web of Science ®Google Scholar
• Shram MJ, Spencer RH, Qian J, et al. Evaluation of the abuse potential of difelikefalin, a selective kappa-opioid receptor agonist, in recreational polydrug users. Clin Transl Sci. 2021;15(2):535–547.
   Web of Science ®Google Scholar
• Viscusi ER, Torjman MC, Munera CL, et al. Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: a randomized, double-blind, placebo-controlled trial. Clin Transl Sci. 2021;14(5):1886–1893.
   PubMed Web of Science ®Google Scholar
• Albert-Vartanian A, Boyd MR, Hall AL, et al. Will peripherally restricted kappa-opioid receptor agonists (pKoras) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Therapeutics. 2016;41(4):371–382. DOI:10.1111/jcpt.12404
   PubMed Web of Science ®Google Scholar
• Fishbane S, Mathur V, Germain MJ, et al. Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients. Kidney Int Rep. 2020;5(5):600–610. DOI:10.1016/j.ekir.2020.01.006
   PubMed Web of Science ®Google Scholar
• Ahdoot R, Kalantar-Zadeh K, McCafferty K, et al. POS-601 IMPROVEMENT in SLEEP QUALITY from REDUCTION of ITCH INTENSITY in PATIENTS with MODERATE-TO-SEVERE PRURITUS UNDERGOING HEMODIALYSIS. Kidney Int Rep. 2022;7(2):S258. DOI:10.1016/j.ekir.2022.01.634
   Google Scholar
• Fishbane S, Clegg DJ, Lerma EV, et al. Safety and efficacy of difelikefalin in black or African American Patients on Hemodialysis with CKD-Associated Pruritus: pooled Analysis of KALM-1 and KALM-2. Abstract PO0805; American Society of Nephrology Kidney Week; November 4, 2021; Virtual
   Google Scholar
• Fishbane S, Walpen S, Schaufler T, et al. 405 effect of treatment with difelikefalin on itch severity in patients with chronic kidney disease-associated pruritus measured by the patient global impression of change. Am J Kidney Diseases. 2022;79(4):S123.
   Web of Science ®Google Scholar
• Csiky B, Walpen S, Schaufler T, et al. MO467: time to Improvement of Itch Intensity in Patients with Chronic Kidney Disease-Associated Pruritus Treated with Difelikefalin. Nephrol Dialysis Transplantation. 2022;37(Supplement_3):gfac070.081.
   Google Scholar
• Weiner DE, Vervloet MG, Walpen S, et al. Kidney Medicine. 2022;4(10):100542. DOI:10.1016/j.xkme.2022.100542.
   PubMedGoogle Scholar
• Weiner DE, Walpen S, Schaufler T, et al. Itch Reduction with Difelikefalin Correlates with Improved Sleep Quality in Hemodialysis Patients with Pruritus. In: Abstract FR-OR26; American Society of Nephrology Kidney Week; November 5, 2021; Virtual.
   Google Scholar
• Weiner D, Budden J, Woods S, et al. 406 Improvement in Itch-Related Sleep Disruption with Difelikefalin in Patients with Moderate to Severe Chronic Kidney Disease Associated Pruritus Undergoing Hemodialysis: a Post Hoc Analysis of an Open-Label, Multicenter Study. Am J Kidney Diseases. 2022;79(4):S124.
   Web of Science ®Google Scholar
• Weiner DE, Vervloet MG, Menzaghi F, et al. Improvement of Itch with Difelikefalin in CKD Patients on Dialysis by Baseline Itch Severity. Abstract SA-PO286; American Society of Nephrology Kidney Week; November 5, 2022; Florida, U.S.A.
   Google Scholar
• Vernon M, Ständer S, Munera C, et al. Clinically meaningful change in itch intensity scores: an evaluation in patients with chronic kidney disease-associated pruritus. J Am Acad Dermatol. 2021;84(4):1132–1134.
   PubMed Web of Science ®Google Scholar
• Hays RD, Kallich JD, Mapes DL, et al. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res. 1994;3(5):329–338.
   PubMed Web of Science ®Google Scholar
• Scott W, McCracken LM. Patients’ impression of change following treatment for chronic pain: global, specific, a single dimension, or many? J Pain. 2015;16(6):518–526.
   PubMed Web of Science ®Google Scholar
• Johansen KL, Chertow GM, Foley RN, et al. US Renal Data System 2020 Annual Data Report: epidemiology of Kidney Disease in the United States. Am J Kidney Diseases. 2021;77(4):A7–8. DOI:10.1053/j.ajkd.2021.01.002
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study to evaluate the safety and efficacy of difelikefalin in advanced chronic kidney disease patients with moderate-to-severe pruritus and not on dialysis. 2019. [cited 2023 Apr]. Available from: https://clinicaltrials.gov/ct2/show/NCT05342623
   Google Scholar
• European Medicines Agency. European Medicines Agency decision. 2020. [cited 2023 Apr]. Available from: https://www.ema.europa.eu/en/documents/pip-decision/p/0172/2020-ema-decision-13-may-2020-agreement-paediatric-investigation-plan-granting-deferral-granting_en.pdf
   Google Scholar
• Australian Government Department of Health and Aged Care. Prescription medicine decision summary. 25 Nov 2022. [cited 2023 Apr]. Available from: https://www.tga.gov.au/resources/auspmd/korsuva
   Google Scholar
• Health Sciences Authority. New drug approvals - August 2022. [cited 2023 Apr]. Avaialble from: https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---august-2022
   Google Scholar
• Swissmedic. Kapruvia prescribing information. 2022. [cited 2023 Apr]. Availble from: https://www.swissmedicinfo.ch/ViewMonographie
   Google Scholar
• Health Canada. Summary basis of decision- Korsuva. 2022. [cited 2023 Apr]. Available from: https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en&linkID=SBD00615&lang=en
   Google Scholar
• SONG Executive Committee. Standardised Outcomes in Nephrology Initiative. 2021. [cited 2023 Apr]. Available from:https://songinitiative.org/
   Google Scholar
• Kalantar-Zadeh K, Lockwood MB, Rhee CM, et al. Patient-centred approaches for the management of unpleasant symptoms in kidney disease. Nat Rev Nephrol. 2022;18(3):185–198. DOI:10.1038/s41581-021-00518-z
   PubMed Web of Science ®Google Scholar
• Davison SN, Levin A, Moss AH, et al. Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care. Kidney Int. 2015;88(3):447–459. DOI:10.1038/ki.2015.110
   PubMed Web of Science ®Google Scholar
• Combs SA, Teixeira JP, Germain MJ. Pruritus in Kidney Disease. Semin Nephrol. 2015;35(4):383–391.
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k Guideline on Chronic Pruritus. Acta Derm Venereol. 2019;99(5):469–506. DOI:10.2340/00015555-3164
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kam-Tao Li P, Tantisattamo E, et al. Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. Kidney Int. 2021;99(2):278–284. DOI:10.1016/j.kint.2020.11.004
   PubMed Web of Science ®Google Scholar